儿童颅咽管瘤患者的囊内干扰素-α治疗:代表SIOPE和ISPN的国际多中心评估
该国际多中心回顾性研究纳入21个中心的56例儿童囊性颅咽管瘤患者,评估囊内干扰素-α的疗效与安全性。囊内干扰素-α较前序治疗延迟囊性病变进展(P=0.0005),干扰素后进展42例(中位14个月),估计至确定性治疗中位时间5.8年,显著副作用少。作者认为可延迟进展并争取手术或放疗时间,毒性较好,但需前瞻性随机国际临床试验评估。
要点
- 囊内干扰素-α较前序治疗延迟囊性颅咽管瘤进展(P=0.0005)。
- 干扰素后进展42例(中位14个月),至确定性治疗估计中位时间5.8年。
- 作者认为需前瞻性随机国际临床试验评估。
核心结论
- 囊内干扰素-α可延迟儿童囊性颅咽管瘤疾病进展,可能延长至确定性手术或放疗的时间,且与其他治疗模式相比毒性较好,但需前瞻性随机国际临床试验评估。
研究设计与样本
- 代表SIOPE和ISPN联系欧洲及国际中心提交数据表,回顾性收集接受囊内干扰素-α的儿童囊性颅咽管瘤患者资料,共21个国际中心56例儿童(中位年龄6.3岁)。
主要发现
- 病变为囊性22例(39%)、囊实性34例(61%),诊断后中位随访5.1年(0.3-17.7年)。
- 干扰素使用前43例(77%)患者曾因既往进展接受治疗,此类病例中囊内干扰素较前序治疗延迟进一步进展(P=0.0005)。
- 干扰素后进展42例(中位14个月;0-8年),干扰素后至确定性治疗的估计中位时间5.8年(1.8-9.7年)。
- 报告的可归因显著副作用少。
临床怎么用
- 作者认为囊内干扰素-α可延迟疾病进展并可能延长至确定性手术或放疗的时间,且毒性较好,但需前瞻性随机国际临床试验评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha. METHODS: European Société Internationale d'Oncologie Pédiatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events, and outcomes were obtained. Progression was clinical or radiological (cyst reaccumulation, novel cysts, or solid growth). RESULTS: Fifty-six children (median age, 6.3 y) from 21 international centers were identified. Median follow-up from diagnosis was 5.1 years (0.3-17.7 y). Lesions were cystic (n = 22; 39%) or cystic/solid (n = 34; 61%). Previous progression was treated in 43 (77%) patients before interferon use. In such cases, further progression was delayed by intracystic interferon compared with the preceding therapy for cystic lesions (P = 0.0005). Few significant attributable side effects were reported. Progression post interferon occurred in 42 patients (median 14 mo; 0-8 y), while the estimated median time to definitive therapy post interferon was 5.8 (1.8-9.7) years. CONCLUSIONS: Intracystic interferon-alpha can delay disease progression and potentially offer a protracted time to definitive surgery or radiotherapy in pediatric cystic craniopharyngioma, yet demonstrates a favorable toxicity profile compared with other therapeutic modalities-important factors for this developing age group. A prospective, randomized international clinical trial assessment is warranted.
引用
- Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol. 2017. PMID: 28499018. doi:10.1093/neuonc/nox056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。